(Avibactam tomilopil + ceftibuten) is under clinical development by Pfizer and currently in Phase I for Urinary Tract Infections. According to GlobalData, Phase I drugs for Urinary Tract Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Avibactam tomilopil + ceftibuten)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Avibactam tomilopil + ceftibuten) overview
(avibactam tomilopil + ceftibuten) is under development for the treatment of complicated urinary tract infections including pyelonephritis. The drug candidate is a combination of PF-06264006 (ceftibuten) and PF-07338233 (AVP).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of (Avibactam tomilopil + ceftibuten)’s drug-specific PTSR and LoA scores, buy the report here.